We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Scientific Method Halves Polio Detection Time

By LabMedica International staff writers
Posted on 23 Aug 2023
Print article
Image: The time to detect polio can be halved using the DDNS technique (Photo courtesy of Freepik)
Image: The time to detect polio can be halved using the DDNS technique (Photo courtesy of Freepik)

Polio, an infectious disease caused by the poliovirus, spreads mainly through contact with contaminated food and water due to infected feces. While some individuals remain asymptomatic, polio can be particularly severe for infants and children under five, resulting in permanent paralysis or even death. The World Health Organization (WHO) recognizes delayed detection as a significant hurdle in their 2022-2026 plan to eradicate polio. Presently, nations with active polio outbreaks ship stool samples worldwide for lengthy, complex lab tests, leading to time-consuming confirmation of results. Detecting polio more swiftly in outbreak regions can allow authorities to respond promptly with focused vaccination efforts, curbing the spread of the virus. Now, a novel technique that has been shown to halve the time to detect polio could support global efforts to eradicate the infectious disease and help save lives.

Collaborative research supported by the Medicines and Healthcare Products Regulatory Agency (MHRA) demonstrated the efficacy of the Direct Molecular Detection and Nanopore Sequencing (DDNS) technique in detecting polio outbreaks. DDNS not only preserves valuable time but also reduces costs for public health bodies. This marks the first application of such a scientific technique for polio detection, building on its use in identifying COVID-19, Ebola, measles, and monkeypox. By enabling in-country testing instead of shipping samples abroad for specialized lab assessments, transport and testing delays shrink from an average of 42 days to 19 days. The research, conducted in the Democratic Republic of Congo (DRC) over six months, exhibited DDNS tests to be approximately 23 days quicker than the standard method, boasting over 99% accuracy.

“We are standing at a delicate and pivotal moment for the eradication of polio. While vaccination programs have seen polio disappear in many countries, the delayed detection of outbreaks poses a major threat to those efforts,” said Javier Martin, Principal Scientist in Virology at the MHRA. “By implementing detection methods such as DDNS, we can identify where outbreaks are and which polio strain is present much more quickly, allowing us to act at the earliest opportunity.”

“This method allows the rapid confirmation of polio strains, facilitating swifter vaccine responses that can reduce the number of polio cases stemming from an outbreak,” said Dr. Alex Shaw, Research Fellow in the School of Public Health at Imperial College London. “The sequencing technology used in this method is easily adapted for the detection and typing of other organisms. This rollout will therefore provide a foundation of skills and experience that can be redirected to the genomic surveillance of other pathogens as needed.”

Related Links:
MHRA 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.